**Core Concept**
Acute intermittent porphyria (AIP) is a rare genetic disorder characterized by the accumulation of porphyrin precursors due to a deficiency in the enzyme porphobilinogen deaminase (PBGD). Management of AIP involves avoiding triggers that can precipitate acute attacks.

**Why the Correct Answer is Right**
The correct answer is **Barbiturates**. Barbiturates can induce the cytochrome P450 enzyme system, particularly CYP1A2, which increases the production of porphyrin precursors. This can trigger an acute attack in patients with AIP. The increased demand for heme synthesis can overwhelm the defective enzyme, leading to the accumulation of neurotoxic intermediates.

**Why Each Wrong Option is Incorrect**
**Option A:** **Sulfonylureas** are not specifically contraindicated in AIP. Although they may be used cautiously, the primary concern with sulfonylureas is their potential to cause hypoglycemia, which is not directly related to porphyria.

**Option B:** **Estrogen-containing contraceptives** can actually be beneficial in some cases of porphyria, as they can help regulate the menstrual cycle and reduce the risk of acute attacks. However, their use should be individualized and monitored carefully.

**Option C:** **Nonsteroidal anti-inflammatory drugs (NSAIDs)** are generally considered safe in AIP, as they do not induce the cytochrome P450 enzyme system to the same extent as barbiturates.

**Clinical Pearl / High-Yield Fact**
In patients with AIP, it is essential to avoid drugs that can induce the cytochrome P450 enzyme system, particularly barbiturates, sulfonamides, and phenytoin. A thorough review of medications is crucial to prevent triggering acute attacks.

**Correct Answer:** A. Barbiturates.